Key result
Low-molecular-weight heparins offer clinical and practical advantages over unfractionated heparin for managing thromboembolic disease in pregnancy, including improved safety.
Why the study?
Does low-molecular-weight heparin improve safety and prevent venous thromboembolism compared to unfractionated heparin in pregnant women?
Does low-molecular-weight heparin improve safety and prevent venous thromboembolism compared to unfractionated heparin in pregnant women?
LMWHs are preferred over unfractionated heparin for managing thromboembolic risk in pregnancy due to improved safety and practical advantages, though optimal treatment protocols remain undefined.
Answers are grounded in this paper and cite their sources.
Supports LMWH preference in pregnancy; leaves optimal dosing and duration protocols undefined.
Thromboembolic complications are leading causes of both maternal and fetal morbidity and mortality. To reduce the incidence of venous thromboembolism (VTE) in pregnancy and improve outcomes, a wider understanding of the risk factors involved and better identification of women at risk of thrombosis are required. Optimal management of thromboembolic disease, both to prevent VTE and to avoid recurrence of pregnancy complications such as miscarriage, centers on the use of low-molecular-weight heparin (LMWH). LMWHs, such as enoxaparin and dalteparin, have clinical and practical advantages compared with unfractionated heparin in terms of improved safety (significantly lower incidence of osteoporosis, thrombocytopenia, and possibly allergic skin reactions) and the potential for outpatient treatment of acute VTE. However, many unanswered questions remain, including who to treat, how to treat them, and when to treat in the case of patients with thrombophilia and a history of previous pregnancy complications.
No takes yet. Share an insight, caveat, or question.
Ian A. Greer (2002) conducted a review in Venous thromboembolism in pregnancy. Low-molecular-weight heparin (LMWH) vs. Unfractionated heparin was evaluated. Low-molecular-weight heparins offer clinical and practical advantages over unfractionated heparin for managing thromboembolic disease in pregnancy, including improved safety.
Synapse has enriched 10 related papers. Consider them for comparative context: